Beyond the Guidelines: Investigator Perspectives on Current Clinical Issues and Ongoing Research in the Management of Early and Advanced Breast Cancer

Proceedings from a CME symposium held at the 2017 ASCO Annual Meeting. Featuring perspectives from Kimberly L Blackwell, Julie R Gralow, Rita Nanda, Mark D Pegram, Hope S Rugo and Eric P Winer.

2.75 AMA PRA Category 1 Credits^™

To complete the Post-test and Educational Assessment and Credit Form, click here. A statement of CME credit will be issued for scores of 80% or better. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

Related links:

Home
CME evaluation
CME information and faculty disclosures
Select publications
PowerPoint slides

Review of Investigator Survey and Audience Polling Results: Choice of Adjuvant Treatment for HER2-Positive Breast Cancer (BC), Including Consideration of Adjuvant Pertuzumab and Postadjuvant Neratinib, and Therapeutic Decision-Making in the Neoadjuvant Setting
Presentation: Adjuvant and Neoadjuvant Therapy for HER2-Positive BC — Dr Winer
Review of Investigator Survey and Audience Polling Results: Utility of Genomic Assays in the Adjuvant, Neoadjuvant and Extended-Adjuvant Settings
Presentation: Use of Genomic Assays and Biomarkers to Assist in the Management of ER-Positive Early BC — Dr Gralow
Review of Investigator Survey and Audience Polling Results: Treatment for Patients with de Novo ER-Positive, HER2-Negative Metastatic BC (mBC) and Those in First and Second Relapse
Presentation: Selection and Sequence of Therapy for Patients with ER-Positive, HER2-Negative mBC — Dr Blackwell
Review of Investigator Survey and Audience Polling Results: Sequencing Therapies for Advanced HER2-Positive Disease
Presentation: Long-Term Management of HER2-Positive mBC — Dr Pegram
Review of Investigator Survey and Audience Polling Results: BRCA Testing and Incorporation of PARP Inhibitors for Patients with ER-Positive/HER2-Negative and Triple-Negative Breast Cancer and BRCA Mutations
Presentation: Potential Role of PARP Inhibition in the Management of BC — Dr Nanda
Presentation: Novel Agents and Strategies Under Active Investigation in BC — Dr Rugo